PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.
Recent technological advancements have provided unprecedented insights into the inflammatory mechanisms underlying liver fibrosis, leading to the identification of promising novel targets for anti-inflammatory and antifibrotic therapies.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD) has emerged as a leading cause of chronic liver disease, affecting a staggering 30% of the global population.
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 38% of adults worldwide, a statistic which is expected to increase with the rise of type 2 diabetes and obesity.
The term metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as an alternative to non-alcoholic fatty liver disease (NAFLD)’s exclusionary nomenclature.
Peroxisome proliferated-activated receptors (PPARs), including α, β/δ and γ isotypes, are a nuclear receptor family of lipid sensors activated by natural fatty acid derivatives and pharmacological agonists.
Tissue fibrosis is induced by an excessive collagen deposition in organs suffering from inflammation and is associated with several diseases, including non-alcoholic steatohepatitis (NASH).
Over the past few decades, non-alcoholic fatty liver disease (NAFLD) has become a growing problem, alongside the increasing rates of obesity and type 2 diabetes.
In this study, a large, global, multidisciplinary panel discussed priorities within the field of fatty liver disease, including its burden, policies surrounding the issue and treatment options.
Currently, there are rising levels of non-alcoholic fatty liver disease (NAFLD). With this, comes a concurrent increase in hepatocellular carcinoma (HCC) cases.
Cardiometabolic syndrome (CMS) involves a complex interplay of many issues, involving obesity, metabolic dysregulation, cardiovascular disease, insulin resistance and more. This condition extends to clinical implications including non-alcoholic fatty liver disease (NAFLD) as well as cancer and sleep apnoea.
Despite its health complications and inherent intra- and inter-observer variability, liver biopsy remains the gold standard for the detection of non-alcoholic steatohepatitis (NASH).
Research into personalised medicine for non-alcoholic fatty liver disease (NAFLD) underscores the importance of acknowledging NAFLD patients’ unique clinical phenotypes when developing targeted pharmacotherapies.